Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRA trades at $9.23 with a market cap of $82.44M and a P/E ratio of 3.63. ATRA moved +0.96% today. Year to date, ATRA is -43.95%; over the trailing twelve months it is +35.00%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atara Biotherapeutics Upgraded to Buy with $13 Target After FDA Clears Tabelecleucel Path: Canaccord Genuity upgraded Atara Biotherapeutics to Buy with a $13.00 price target, implying about 31% upside from its $9.93 close. A productive FDA meeting cleared a single-arm study pathway for tabelecleucel, triggering a 92.82% share surge on over 75 million shares traded.
| Metric | Value |
|---|---|
| Price | $9.23 |
| Market Cap | $82.44M |
| P/E Ratio | 3.63 |
| EPS | $2.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.15 |
| 52-Week Low | $3.92 |
| Volume | 47 |
| Avg Volume | 0 |
| Revenue (TTM) | $120.77M |
| Net Income | $32.69M |
| Gross Margin | 0.00% |
2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.